nach oben

Current Rheumatology Reports

Erschienen in:

01.04.2012 | PEDIATRIC RHEUMATOLOGY (TJA LEHMAN, SECTION EDITOR)

Pediatric Vasculitis

verfasst von: Ezgi Deniz Batu, Seza Ozen

Erschienen in: Current Rheumatology Reports | Ausgabe 2/2012

Einloggen, um Zugang zu erhalten

Abstract

The primary systemic vasculitides in childhood are quite rare except for Henoch-Schönlein purpura and Kawasaki disease. These are usually self-limited diseases. The etiopathogenesis for most of them is not clearly understood. However, it is usually thought that environmental triggers (mostly infectious) evoke an aggravated inflammatory response in susceptible individuals. The classification criteria for most of them were recently validated for children. Clinical manifestations are determined by the organs affected, reflecting the involved vessels on a background of constitutional symptoms. For treatment, the main data are adapted from adult studies, especially for rarer vasculitides in childhood. In this review, the recent classification criteria, current pathophysiologic pathways, and treatment protocols are summarized.

Brogan PA, Dillon MJ. Vasculitis from the pediatric perspective. Curr Rheumatol Rep. 2000;2:411–6.PubMedCrossRef

Rowley AH, Ozen S, Sundel RP, et al. A clinician’s pearls and myths in rheumatology. London: Springer; 2009. p. 219–29.CrossRef

Ozen S. Problems in classifying vasculitis in children. Pediatr Nephrol. 2005;20:1214–8.PubMedCrossRef

Ruperto N, Ozen S, Pistorio A, et al. EULAR/PRINTO/PRES criteria for Henoch-Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part I: overall methodology and clinical characterization. Ann Rheum Dis. 2010;69:790–7.PubMedCrossRef

•• Ozen S, Pistoiro A, Iusan SM, et al. EULAR/PRINTO/PRES criteria for Henoch-Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: Final classification criteria. Ann Rheum Dis. 2010;69:798–806. This is the criteria validation for most of the vasculitides in childhood. PubMedCrossRef

Ozen S, Ruperto N, Dillon MJ, et al. EULAR/PRES endorsed consensus criteria for the classification of childhood vasculitides. Ann Rheum Dis. 2006;65:936–41.PubMedCrossRef

Allen DM, Diamond LK, Howell DA. Anaphylactoid purpura in children. Am J Dis Child. 1960;99:833–54.

Gedalia A. Henoch-Schönlein purpura. Curr Rheumatol Rep. 2004;6:195–202.PubMedCrossRef

Saulsbury FT. Epidemiology of Henoch-Schönlein purpura. Cleve Clin J Med. 2002;69:SII87–9.PubMedCrossRef

10.

Lau KK, Wyatt RJ, Moldoveanu Z, et al. Serum levels of galactose-deficient IgA in children with IgA nephropathy and Henoch-Schönlein purpura. Pediatr Nephrol. 2007;22:2067–72.PubMedCrossRef

11.

Kawasaki Y, Suyama K, Yugeta E, et al. The incidence and severity of Henoch-Schönlein purpura nephritis over a 22-year period in Fukushima prefecture, Japan. Int Urol Nephrol. 2010;42:1023–9.PubMedCrossRef

12.

Kawasaki Y. The pathogenesis and treatment of pediatric Henoch-Schönlein purpura nephritis. Clin Exp Nephrol 2011, In press.

13.

Shin JI, Song KS, Kim H, et al. The gene expression profile of matrix metalloproteinases and their inhibitors in children with Henoch-Schönlein purpura. Br Assoc Dermatol. 2011;164:1348–55.CrossRef

14.

Chen T, Guo Z-P, Li M-M, et al. Tumor necrosis factor-like weak inducer of apoptosis (TWEAK), an important mediator of endothelial inflammation, is associated with the pathogenesis of Henoch-Schönlein purpura. Clinical and Experimental Immunology 2011, In press.

15.

Brogan P, Bagga A. Leukocytoclastic vasculitis. In: Cassidy JT, Petty RE, Laxer RM, et al., editors. Textbook of pediatric rheumatology. Philadelphia: Saunders Elsevier; 2011. p. 482–97.

16.

Roberts PF, Waller TA, Brinker TM, et al. Henoch-Schönlein purpura: a review article. South Med J. 2007;100(8):821–4.PubMedCrossRef

17.

Chen S-Y, Kong M-S. Gastrointestinal manifestations and complications of Henoch-Schönlein purpura. Chang Gung Med. 2004;27:175–81.

18.

Narchi H. Risk of long term renal impairment and duration of follow up recommended for Henoch-Schönlein purpura with normal or minimal urinary findings: a systematic review. Arch Dis Child. 2005;90:916–20.PubMedCrossRef

19.

Saulsbury FT. Clinical update: Henoch-Schönlein purpura. Lancet. 2007;369(9566):976–8.PubMedCrossRef

20.

Rostoker G. Schönlein-Henoch purpura in children and adults: diagnosis, pathophysiology and management. BioDrugs. 2001;15(2):99–138.PubMedCrossRef

21.

Ozen S. The spectrum of vasculitis in children. Best Pract Res Clin Rheumatol. 2002;16(3):411–25.PubMed

22.

•• Davin J-C. Henoch-Schönlein purpura nephritis: pathophysiology, treatment and future strategy. Clin J Am Soc Nephrol. 2011;6:679–89. This is an excellent review describing the treatment strategies on pathogenetic pathways in HSP. PubMedCrossRef

23.

Bergstein J, Leiser J, Andreoli SP. Response of crescentic Henoch-Schönlein purpura nephritis to corticosteroid and azathioprine therapy. Clin Nephrol. 1998;49(1):9–14.PubMed

24.

Flynn JT, Smoyer WE, Bunchman TE, et al. Treatment of Henoch-Schönlein purpura glomerulonephritis in children with high-dose corticosteroids plus oral cyclophosphamide. Am J Nephrol. 2001;21:128–33.PubMedCrossRef

25.

Goldstein AR, White RHR, Akuse R, et al. Long term follow-up of childhood Henoch-Schönlein nephritis. Lancet. 1992;339:280–2.PubMedCrossRef

26.

Wakaki H, Ishikura K, Hataya H, et al. Henoch-Schönlein purpura nephritis with nephrotic state in children: predictors of poor outcomes. Pediatr Nephrol. 2011;26:921–5.PubMedCrossRef

27.

Shulman ST, Rowley AH. Advances in Kawasaki disease. Eur J Pediatr. 2004;163:285–91.PubMedCrossRef

28.

De Rosa G, Pardeo M, Rigante D. Current recommendations for the pharmacologic therapy in Kawasaki syndrome and management of its cardiovascular complications. Eur Rev Med Pharmacol Sci. 2007;11:301–8.PubMed

29.

Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Pediatrics. 2004;114:1708–33.PubMedCrossRef

30.

Burns JC, Glode MP. Kawasaki syndrome. Lancet. 2004;364:533–44.PubMedCrossRef

31.

Yanagawa H, Nakamura Y, Kawasaki T, et al. Nationwide epidemics of Kawasaki disease in Japan during winter of 1985–86. Lancet. 1986;2(8516):1138–9.PubMedCrossRef

32.

Burgner D, Davilla S, Breunis WB, et al. International Kawasaki Disease Genetic Consortium: a genome-wide association study identifies novel and functionally related susceptibility loci for Kawasaki disease. PloS Genet. 2009;5(1):e1000319.PubMedCrossRef

33.

Oh JH, Han JW, Lee SJ, et al. Polymorphisms of human leukocyte antigen genes in Korean children with Kawasaki disease. Pediatr Cardiol. 2008;29:402–8.PubMedCrossRef

34.

Hsieh Y-Y, Lin Y-J, Chang C-C, et al. Human lymphocyte antigen B-associated transcripts 2,3 and 5 polymorphisms and haplotypes are associated with susceptibility of Kawasaki disease and coronary artery aneurysm. J Clin Lab Anal. 2010;24:262–8.PubMedCrossRef

35.

Yeo Y, Kim T, Ha K, et al. Incomplete Kawasaki disease in patients younger than 1 year of age: a possible inherent risk factor. Eur J Pediatr. 2009;168:157–62.PubMedCrossRef

36.

Levy M, Karen G. Atypical Kawasaki disease: analysis of clinical presentation and diagnostic clues. Pediatr Infect Dis J. 1990;9:122–6.PubMedCrossRef

37.

Pinna GS, Kafetzis DA, Tselkas OI, et al. Kawasaki disease: an overview. Curr Opin Infect Dis. 2008;21:263–70.PubMedCrossRef

38.

Galeotti C, Bayry J, Kone-Paut I, et al. Kawasaki disease: aetiopathogenesis and therapeutic utility of intravenous immunoglobulin. Autoimmun Rev. 2010;9:441–8.PubMedCrossRef

39.

•• Falcini F, Capannini S, Rigante D. Kawasaki syndrome: an intriguing disease with numerous unsolved dilemmas. Pediatr Rheumatol. 2011;In press. This is the most recent review defining clearly the challenges in KD.

40.

Tse SM, Silverman ED, Mc Crindle BW, et al. Early treatment with intravenous immunoglobulin in patients with Kawasaki disease. J Pediatr. 2002;140:450–5.PubMedCrossRef

41.

Sugahara Y, Ishii M, Muta H, et al. Warfarin therapy for giant aneurysm prevents myocardial infarction in Kawasaki disease. Pediatr Cardiol. 2008;29:398–401.PubMedCrossRef

42.

Furukawa T, Kishiro M, Akimoto M, et al. Effects of steroid pulse therapy on immunoglobulin-resistant Kawasaki disease. Arch Dis Child. 2008;93:142–6.PubMedCrossRef

43.

McCrindle BW. Kawasaki disease: a childhood disease with important consequences into adulthood. Circulation. 2009;120:6–8.PubMedCrossRef

44.

Ozen S, Bakkaloglu A, Dusunsel R, et al. Childhood vasculitis in Turkey: a nationwide survey. Clin Rheumatol. 2007;26:196–200.PubMed

45.

Ozen S, Anton J, Arisoy N, et al. Juvenile polyarteritis: results of a multicenter survey of 110 children. J Pediatr. 2004;145:517–22.PubMedCrossRef

46.

Ozen S, Ben-Chetrit E, Bakkaloglu A, et al. Polyarteritis nodosa associated with familial mediterranean fever: is it an association? Semin Arthritis Rheu. 2001;30:281–7.CrossRef

47.

Wright E, Dillon MJ, Tullus K. Childhood vasculitis and plasma exchange. Eur J Pediatr. 2007;166:145–51.PubMedCrossRef

48.

Schmidt WA. Use of imaging studies in the diagnosis of vasculitis. Curr Rheumatol Rep. 2004;6:203–11.PubMedCrossRef

49.

Dillon MJ, Eleftherious D, Brogan PA. Medium-size-vessel vasculitis. Pediatr Nephrol. 2010;25:1641–52.PubMedCrossRef

50.

Dillon MJ. Vasculitis treatment: new therapeutic approaches. Eur J Pediatr. 2006;165:351–7.PubMedCrossRef

51.

Jayne D, Rasmussen N, Andrassy K, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med. 2003;349:36–44.PubMedCrossRef

52.

Fernanda F, Serena C, Giustina R, et al. Mycophenolate mofetil treatment in two children with severe polyarteritis nodosa refractory to immunosuppressant drugs. Rheumatol Int. 2011;In press.

53.

Fathalla BM, Miller L, Brady S, et al. Cutaneous polyarteritis nodosa in children. J Am Acad Dermatol. 2005;53:724–8.PubMedCrossRef

54.

David J, Ansell BM, Woo P. Polyarteritis nodosa associated with streptococcus. Arch Dis Child. 1993;69:685–8.PubMedCrossRef

55.

Radice A, Sinico RA. Antineutrophil cytoplasmic antibodies (ANCA). Autoimmunity. 2005;38:93–103.PubMedCrossRef

56.

Gardner-Medwin JM, Dolezalova P, Cummins C, et al. Incidence of Henoch-Schönlein purpura, Kawasaki disease, and rare vasculitides in children of different ethnic origins. Lancet. 2002;360(9341):1197–202.PubMedCrossRef

57.

Vamvakopoulos J, Savage CO, Harper L. ANCA-associated vasculitides—lessons from the adult literature. Pediatr Nephrol. 2010;25:1397–407.PubMedCrossRef

58.

Zwerina J, Eger G, Englbrecht M, et al. Churg-Strauss syndrome in childhood: a systematic literature review and clinical comparison with adult patient. Semin Arthritis Rheum. 2008;39:108–15.PubMedCrossRef

59.

Akikusa JD, Schneider R, Harvey EA, et al. Clinical features and outcome of pediatric Wegener’s granulomatosis. Arthritis & Rheumatism. 2007;52(5):837–44.CrossRef

60.

Vanoni F, Bettinelli A, Keller F, et al. Vasculitides associated with IgG antineutrophil cytoplasmic autoantibodies in childhood. Pediatr Nephrol. 2010;25:205–12.PubMedCrossRef

61.

Kerr GS, Hallahan CW, Giordano J, et al. Takayasu arteritis. Ann Intern Med. 1994;120:919–29.PubMed

62.

Sharma BK, Sagar S, Chugh KS, et al. Spectrum of renovascular hypertension in the young in north India. Angiology. 1985;36:370–8.PubMedCrossRef

63.

Lane SE, Watts R, Scott DG. Epidemiology of systemic vasculitis. Curr Rheumatol Rep. 2005;7:270–5.PubMedCrossRef

64.

Vanoli M, Daina E, Salvarini C, et al. Takayasu arteritis: a study of 104 Italian patients. Arthritis Rheum. 2005;53:100–7.PubMedCrossRef

65.

Hahn D, Thomson PD, Kala U, et al. A review of Takayasu’s arteritis in children in Gauteng, South Africa. Pediatr Nephrology. 1998;12:668–75.CrossRef

66.

•• Morishita KA, Rosendahl K, Brogan P. Familial Takayasu arteritis—a pediatric case and a review of the literature. Pediatr Rheum. 2011;In press. This is a recent review of familial TA cases in the literature encouraging the search for candidate genes in TA pathogenesis.

67.

Cakar N, Yalcinkaya F, Duzova A, et al. Takayasu arteritis in children. J Rheumatol. 2008;35:913–9.PubMed

68.

Yamada I, Nakagawa T, Himero Y, et al. Takayasu arteritis: diagnosis with breath hold contrast enhanced 3-dimensional MR angiography. J Magn Reson Imaging. 2000;II:481–7.CrossRef

69.

Koening CL, Langford CA. Novel therapeutic strategies for large vessel vasculitis. Rheum Dis Clin North Am. 2006;32:173–86.PubMedCrossRef

70.

Ozen S, Duzova A, Bakkaloglu A, et al. Takayasu arteritis in children: preliminary experience with cyclophosphamide induction and corticosteroids followed by methotrexate. J Pediatr. 2007;150:72–6.PubMedCrossRef

71.

Liang P, Hoffman GS. Advances in the medical and surgical treatment of Takayasu arteritis. Curr Opin Rheumatol. 2005;12:16–24.CrossRef

72.

Lee GY, Jang SY, Ko SM, et al. Cardiovascular manifestations of Takayasu arteritis and their relationship to the disease activity: analysis of 204 Korean patients at a single center. Int J Cardiol. 2011;In press.

73.

Ozen S. The ‘other’ vasculitic syndromes and kidney involvement. Pediatr Nephrol. 2010;25(9):1633–9.PubMedCrossRef

74.

Mahr A, Belarbi L, Wechsler B, et al. Population-based prevalence study of Behçet’s disease: differences by ethnic origin and low variation by age at immigration. Arthritis Rheum. 2008;58:3951–9.PubMedCrossRef

75.

Calamia KT, Wilson FC, Icen M, et al. Epidemiology and clinical characteristics of Behçet’s disease in the US: a population-based study. Arthritis Rheum. 2009;61:600–4.PubMedCrossRef

76.

•• Ozen S. Pediatric onset Behçet disease. Curr Opin Rheumatol. 2010;22:585–89. This is a recent review of childhood Behçet’s syndrome. PubMedCrossRef

77.

• Fei Y, Webb R, Cobb BL, et al. Identification of novel genetic susceptibility loci for Behçet’s disease using a genome-wide association study. Arthritis Res Ther. 2009;11:R66. This was the first GWAS in Behçet’s syndrome. PubMedCrossRef

78.

Mizuki N, Meguro A, Ota M, et al. Genome-wide association studies identify IL23R-IL12RB2 and IL10 as Behcet’s disease susceptibility loci. Nat Genet. 2010;42(8):703–6.PubMedCrossRef

79.

International Study Group for Behcet’s Disease. Criteria for diagnosis of Behçet’s disease. Lancet. 1990;335:1078–80.

80.

Hatemi G, Silman A, Bang D, et al. EULAR Expert Committee, EULAR recommendations for the management of Behçet disease. Ann Rheum Dis. 2008;67:1656–62.PubMedCrossRef

81.

Cantarini L, Tinazzi I, Caramaschi P, et al. Safety and efficacy of etanercept in children with juvenile-onset Behcet’s disease. Int J Immunopathol Pharmacol. 2009;22:551–5.PubMed

Titel: Pediatric Vasculitis
verfasst von: Ezgi Deniz Batu
Seza Ozen
Publikationsdatum: 01.04.2012
Verlag: Current Science Inc.
Erschienen in: Current Rheumatology Reports / Ausgabe 2/2012
Print ISSN: 1523-3774
Elektronische ISSN: 1534-6307
DOI: https://doi.org/10.1007/s11926-011-0232-4

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2012

Current Understanding of the Pathogenesis and Management of Chronic Recurrent Multifocal Osteomyelitis

Update on the Phenotypic Spectrum of Lesch-Nyhan Disease and its Attenuated Variants

Granulomatosis with Polyangiitis in Childhood

What Do Cytokine Profiles Tell Us About Subsets of Juvenile Idiopathic Arthritis?

Genetics and Mechanisms of Crystal Deposition in Calcium Pyrophosphate Deposition Disease